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ABSTRACT  
Patients with psoriasis have a high prevalence of diabetes mellitus (DM), obesity and 
cardiovascular diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists is a recent 
therapy used in obese patients with type 2 diabetes. This new drugs improve glycaemic 
control and reduce weight. Besides, GLP-1R is present on some cells of the immune system. 
Recent studies suggested that GLP-1R agonists may improve psoriasis. 
We reviewed the literature to examine the efficacy of GLP-1R agonists on clinical severity of 
psoriasis patients with obesity and type 2 diabetes and to evaluate the mechanism by which 
GLP-1R agonists exert their effects. Psoriasis patients, with type 2 diabetes and obesity, seem 
to have a significant improvement in psoriasis severity and quality of life, after GLP-1R 
agonist therapy. They also showed a decreased in weight and cholesterol levels and an 
improvement in glycaemic control.  The effects on psoriatic lesions occur after a few weeks 
of treatment, even before the metabolic improvement occurs. GLP-1R agonists appear to have 
an added beneficial effect on psoriasis patients, possibly due to its immunomodulatory effects. 
Furthermore, this treatment can also improve other comorbidities that may be associated, such 
as diabetes and obesity. In conclusion, GLP-1R agonists may be a useful adjunctive therapy 
for the treatment of psoriasis in diabetics and obese patients. 
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INTRODUCTION 
Psoriasis is a chronic inflammatory disease that affects 2-3% of world’s population. 
Histopathologically is characterized by hiperproliferation of epidermal keratinocytes and 
hyperkeratosis, dermal inflammatory infiltrate and angiogenesis. The inflammatory infiltrate 
consists mainly of dendritic cells, macrophages, and T cells in the dermis and neutrophils, 
with some T cells in the epidermis (1, 2). Psoriasis is considered an immune-mediated 
inflammatory skin disorder (3), in which Th17 pathway plays an important role (1), supported 
by the good results with IL-17 based therapies (4). 
Psoriasis was considered a disease confined to the skin (5), but recent findings have shown 
that patients with psoriasis also have an increased risk of cardiovascular disease and mortality, 
as well as metabolic syndrome and its components (6-8). Several studies have shown that 
patients with psoriasis have a high prevalence of DM, hypertension, obesity, hyperlipidaemia 
and smoking (9-11). So, it is important to approach psoriasis as a systemic disorder.  
Psoriasis patients have a higher risk of developing impaired glucose tolerance and type 2 
diabetes (12-14). Obesity seems to be more common in psoriasis patients when compared 
with the general population (15) and is considered a risk factor for the development of 
psoriasis (6). The reason behind this association remains unknown, but different studies 
suggest that obesity, as a chronic inflammatory state, may contribute to the development and 
aggravation of psoriatic lesions (16, 17).  
Two new drug classes based on the actions of the incretin hormones have been approved for 
therapy of type 2 diabetes - incretin enhancers and incretin mimetics (18). Inhibitors of 
dipeptidyl peptidase 4 (DPP4 - the enzyme responsible for the rapid degradation of GLP-1), 
increase incretins levels and enhance GLP-1 action. It is  known that DPP4 is also expressed 
on T cells surface, having an important role in activating T cells (19). However, only two 
cases reports showed that DPP4 inhibitors have positive effects in the treatment of psoriasis 
patients with diabetes (19, 20). Glucagon-like peptide-1 receptor (GLP-1R) agonists (incretin 
mimetics – liraglutide and exenatide) have been used in obese patients with type 2 diabetes. 
This therapy improves glycaemic control and reduces weight. Several studies suggest that 
psoriasis patients with obesity and DM2, treated with GLP-1R agonists, exhibited a 
significant improvement of psoriasis lesions, possibly due to its anti-inflammatory effect (21).  
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Therefore, we reviewed the literature to examine the efficacy of treatment with GLP-1R 
agonists in psoriasis patients with obesity and type 2 diabetes and evaluate the mechanism by 
which GLP-1R exert their effects.  
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METHODS 
We performed a literature review in November 2014 that associated psoriasis and treatment 
with GLP-1R agonists. The methodological approach included the design of selection criteria, 
definition of research strategies, trial quality and choice of relevant information. 
We search MEDLINE, SCOPUS and Web of Science using the following search criteria: 
("psoriasis"[MeSH Terms] OR "psoriasis"[All Fields]) AND ("glucagon-like peptide 
1"[MeSH Terms] OR "glucagon-like peptide 1"[All Fields] OR "glp 1"[All Fields]).  
Our search was limited to articles available in English; case reports, case-control, cross 
sectional, cohort or clinical trial design. Articles not mentioning methods or the results, 
systematic reviews and meeting abstracts were excluded. Since the treatment with GLP-1R 
agonists is quite recent, no articles were found before 2011. 
In the first phase, the titles and abstracts of the articles were reviewed by the investigators. In 
the second we analysed, independently, articles which have been identified as potentially 
important. The selection criteria were then applied and decided the articles that had to be 
excluded.  
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RESULTS 
A total of 84 articles were identified from the initial research and 17 of these were excluded 
since they were duplicated articles. After reviewing all titles and abstracts 55 articles were 
excluded. Then 12 full-text articles were analysed and inclusion criteria applied. In the end, 4 
articles were excluded (3 reviews and 1 french article) and 8 articles were included in this 
review (figure1). 
A prospective cohort study by T. Ahern et al (table 1) was conducted to determine the effect 
of liraglutide on psoriasis severity. Seven patients (median age 48 years, median body mass 
index 48.2 kg⁄m2), with mild chronic plaque psoriasis and diabetes, were followed. Psoriasis 
area and severity index (PASI), dermatology life quality index (DLQI), circulating 
lymphocyte subset numbers and monocyte cytokine production were determined before and 
after 10 weeks of liraglutide therapy. Liraglutide therapy improved psoriasis severity and 
quality of life. The median interquartile range (IQR) PASI dropped 1.8 (P = 0.03) and a 
reduction of over 50% in the PASI was observed in two patients (29%).  The median (IQR) 
DLQI dropped from 6 (3.5–8.9) to 2 (1–6.1, P = 0.03).  Weight and glycaemic control also 
improved significantly. There was a weight loss of 5% (IQR: 1.8–10.2%) and fasting plasma 
glucose concentration decreased from 6.1 mmol⁄L (5.6–6.6 mmol⁄L) to 5.8 mmol⁄L (5.1–6.2 
mmol⁄L, P = 0.08). An increase of 37.9% on circulating invariant natural killer T (iNKT) cell 
percentage and a decrease of 53% on the proportion of monocytes that produced tumour 
necrosis factor alfa was also observed. Liraglutide therapy did not result in changes of the 
number of circulating T lymphocytes, B lymphocytes or natural killer (NK) cells. (22) 
A randomized placebo-controlled trial of 20 obese patients with plaque psoriasis and without 
diabetes, showed no effect of liraglutide on psoriasis after 8 weeks of treatment with 
liraglutide when compared to placebo. No significant difference was observed in PASI, 
comparing the two groups (P = 0.228). However liraglutide treated patients had a significant 
decrease in PASI (-2.6 ± 2.1). No significant difference in DLQI occurred. Liraglutide 
treatment induced a significant weight loss and decrease in cholesterol levels in patients with 
psoriasis. No changes on HbA1c occurred during the treatment in both groups. No serious 
adverse events were observed and 45% of the patients treated with liraglutide experienced 
nausea. (23) 
In a study by M. Buysschaert et al, seven patients with type 2 diabetes and psoriasis were 
followed for 20 weeks of treatment with GLP-1 analogue. They measured the psoriasis area 
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and severity (PASI), the epidermal thickness, the dermal γδ T cell percentage and the 
expression of interleukin (IL)-17 at the beginning of the treatment (T0) and 7±1 weeks (T1) 
and 18±2 weeks (T2) after treatment. A decreased of 1.4 ± 1.0 kg m -2 in BMI was observed 
after 4-5 months of treatment (p = 0.05) and HbA1c also decreased from 7.5±1.2% to 6.5 ± 
0.8%, after 18 weeks of treatment. Psoriasis lesions improved, with mean PASI dropping 
from 12.0 ± 5.9 (at T0) to 9.2 ± 6.2 at T1 (p = 0.008 vs T0) and 9.2 ± 6.4 at T2 (p = 0.04 vs 
T0, not significance vs T1). The dermal γδ T-cell percentage and IL-17 expression were 
measured in psoriatic and unaffected skin of all patients. The dermal γδ T-cell percentage was 
higher in psoriatic lesions compared with unaffected skin. After 18±2 weeks of treatment, the 
demal γδ T-cell percentage decreased 4.0±0.7% (P=0.05) in patients with improved (n=5) or 
unchanged (n=1) PASI scores. A correlation between the change in PASI (T2 - T0) and 
dermal γδ T-cell percentage (T2 - T0) was seen in all patients (r = 0.894, P = 0.007). The IL-
17 mRNA expression was higher in psoriatic skin vs control. No significance difference was 
seen during the treatment in IL-17 expression. (24) 
Hogan et al observed that a psoriasis patient with type 2 diabetes and BMI 37 Kg/m2 had 
improved psoriasis severity after treatment with GLP-1R analogues (first exenatide for 2 
months and then liraglutide). Therefore, they started liraglutide therapy in another two 
patients with psoriasis and type 2 diabetes. They evaluated PASI, circulatory and plaque 
levels of iNKT cells and GLP-1R expression of iNKT cells in vitro, before and after 6 weeks 
of treatment. Psoriasis severity improved in both patients (PASI improved from 13.2 to 10.8 
in patient 1 and from 4.8 to 3.8 in patient 2). A redistribution of iNKT cells was observed, 
with circulatory iNKT cell number increasing and plaque iNKT cell decreasing after 6 weeks 
of therapy. It was also shown that iNKT cells express GLP-1R in vitro. These cells respond to 
GLP-1, activating a signalling pathway, which ends in cytokine production. (25) 
Faurschou et al designed a study to determine if GLP-1 receptors are expressed in the skin of 
healthy volunteers and psoriasis patients and if these receptors are located on keratinocytes or 
immune cells. They included six healthy volunteers and six patients with psoriasis vulgaris. A 
skin biopsy was made every healthy volunteer and two skin biopsies every psoriasis patients 
(from affected and unaffected skin). They also collected a blood sample from all participants. 
Gene expression analysis showed expression of GLP-1R in five of six skin biopsies from 
psoriasis plaques and no GLP-1R expression from unaffected psoriatic skin (in five skin 
biopsies) and from healthy volunteers (in five skin biopsies). The blood samples from healthy 
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volunteers and psoriasis patients showed GLP-1R expression. Keratinocyte cultures, 
unstimulated and stimulated with TNFα and INFα, didn’t show GLP-1R expression. (26) 
A case report of a 59 years old man (BMI 29.3 kg/m2), with type 2 diabetes and plaque 
psoriasis showed that after 3 months of initiating liraglutide treatment, his psoriasis symptoms 
and severity improved (table 2). He had inadequate glycaemic control and after 12 weeks of 
therapy his HbA1c decreased from 8.9% to 5.9%.  He also lost 7.8kg, reaching a BMI of 26.81 
kg/m2. Plaque psoriasis was diagnosed 15 years ago and has worsened over time, despite 
topical treatment with corticosteroids, vitamin D analogues and narrowband ultraviolet B 
radiation.  With liraglutide treatment psoriasis symptoms improved immediately and 
physician’s global assessment (PGA) reduced after 3 months of treatment. These patient 
started GLP-1R therapy because of his uncontrolled diabetes but additionally he experimented 
a significant improvement of psoriasis, which could be explained by a direct anti-
inflammatory effect of liraglutide. (27) 
A 61 years old man, diabetic for 14 years and obese (BMI 25.5 kg/m2), also showed an 
extensive refractory psoriasis since 1980, treated with multiple steroid (PASI 11). He started 
exenatide therapy (2x5µg/day) on September 2008 to improve his glycaemic control.  After 
one year of treatment his BMI and HbA1c levels reduced significantly, from 25.5 to 24.07 
kg/m2 and 8.1% to 7.3%, respectively. Besides, the patient also reported a great improvement 
in psoriasis lesions, which occurred immediately after one month of treatment. He reached a 
PASI score of 3-4 just in one year (28). 
Reid et al also observed an improvement in psoriasis lesions in one patient after one year of 
treatment with liraglutide. The patient had malignant melanoma, without metastatic disease 
and no diabetes. He previously had been submitted to multiple systemic drugs for psoriasis 
treatment but none were effective. After diagnosis of melanoma he had to discontinue 
Adalimumab. After he began the treatment with liraglutide PASI dropped from 14.2 to 7.6 
and DQLI from 25 to 12 (29). 
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DISCUSSION 
 
Psoriasis patients, with type 2 diabetes and obesity, seem to have a significant improvement in 
psoriasis severity and quality of life, after GLP-1R agonist therapy. They also showed a 
decreased in weight and cholesterol levels and an improvement in glycaemic control (figure 
2).  The effects on psoriatic lesions occurred after a few weeks of treatment, even before the 
metabolic improvement occurs. Still, the only randomized placebo-controlled trial, showed no 
significant change in psoriasis severity after 8 weeks of treatment with liraglutide. The 
patients included in this study had no diabetes, in contrast to other studies that include only 
diabetic patients (17).  
Different mechanisms have been proposed to explain the reason why psoriasis improves with 
this therapy, in diabetic and obese patients. Some authors suggest that it may be related with 
improved glycaemic control and weight loss. Indeed, in the majority of studies, patients who 
had a decrease in psoriasis severity also show lower HbA1c levels and a reduction in BMI. 
(23, 24, 27-29) Obesity is common among patients with psoriasis and they have a higher risk 
of being obese comparing with general population.  Obesity is more prevalent in patients with 
severe psoriasis rather than patients with mild and it seems to aggravate their condition. 
Besides, obese psoriasis patients are often more difficult to treat (15, 16). However, previous 
data indicate that psoriasis severity improves long before changes occur in weight and blood 
glucose, suggesting that the immediate effect of GLP-1R agonists probably is independent of 
glycaemic control and BMI. This is supported by several studies, that show no association 
between clinical improvement of psoriasis, glycaemic control and weight loss (22-25).  
An alternative hypothesis is that GLP-1R agonists may have an immunomodulatory effect, 
interacting directly with cells of the immune system. A study from Faurschou et al 
demonstrated that GLP-1Rs are expressed in human psoriasis plaques and that is due to the 
immune cells infiltration (26). Th17 cells are responsible to produce IL-17, a recent 
therapeutic target, and its number is increased in psoriatic skin lesions. But, the major source 
of IL-17 is a new subset of dermal γδ T-cell, in response to IL-23 stimulation (30). 
M.Buysschaert et al showed that dermal γδ T-cell numbers and IL-17 levels are increased in 
psoriatic lesions when compared with control skin in patients with type 2 diabetes. In 
addition, liraglutide/exenatide therapy was also associated with a decreased number of dermal 
γδ T-cells and IL-17 mRNA expression (24). On the other hand, psoriasis is associated with 
decreased number of circulating NKT cells and increased number of NKT cells in lesional 
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skin from psoriasis patients (31). Cameron et al demonstrated that cells expressing NK 
markers and NK-T cell markers are present in psoriasis lesions (32). Recent data, reported by 
T. Ahern et al and Hogan et al, show that circulating iNKT cells increased and plaque iNKT 
cells decreased after liraglutide treatment in psoriasis patients with type 2 diabetes and 
obesity(22, 25). These results suggest that GLP-1R agonists may have a role in psoriasis 
treatment, since they seem to have direct and indirect effects on immune cells involved in 
psoriasis pathogenesis.  
Other studies have shown that GLP-1 levels also increased after gastric bypass surgery.  Some 
case reports have described that psoriasis improves immediately after this procedure in obese 
patients (33). Changes on psoriasis manifestations occur before any weight loss and coincide 
with a significant increase in GLP-1 levels (34-36). Faurschou et al suggested that GLP-1 is 
responsible for this effect. The changes on GLP-1 levels are presumed to be caused by the 
surgically-introduced rerouting of ingested nutrients directly to the distal part of jejunum, 
where GLP-1 releasing L cells are abundant (figure 2). GLP-1 is secreted to the blood stream 
upon food ingestion when luminal nutritional components contact with the apical part of the L 
cells. These data support the hypothesis that GLP-1 is responsible for the positive effect 
observed in psoriasis and obese patients with type 2 diabetes (37). 
Most of the studies were limited by small sample size, short duration, lack of comparative 
groups and placebo effect. Further studies are obviously needed, including randomised 
clinical trials. GLP-1R agonists appear to have an added beneficial effect on psoriasis 
patients, possibly due to its immunomodulatory effects. Besides, this treatment can also 
improve other comorbidities that may be associated, such as diabetes and obesity.  
In conclusion, GLP-1R agonists seem to have a positive effect on psoriasis severity and 
quality of life. It appears to act by an immune mechanism, through a reduction of IL-17 
expression and dermal γδ T-cells. These results suggest that GLP-1R agonists may be a useful 
adjunctive therapy for the treatment of psoriasis in diabetics and obese patients. 
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Literature search
Total number of abstracts identified 
from database search (MEDLINE, 
SCOPUS, Web of SCIENCE) 
n = 84
Duplicated articles 
(excluded n = 17)
Total number of articles 
n = 67
Articles screened on basis of title 
and abstracts 
(excluded 55)
Included n = 12
Manuscript review and application 
of inclusion criteria
Included n = 8
Excluded n = 4
3 reviews
1 french article
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Diabetes and 
Obesity 
Psoriasis 
GLP-1 
GLP-1 receptor agonists 
Liraglutide and Exenatide 
- prolongs and enhances the effect of GLP-1 
- they are resistant to inactivation by DPP4 
 
Gastric Bypass Surgery 
- Roux-en-Y gastic bypass procedure: a small part of 
the stomach is used to create a new stomach pouch; the 
smaller stomach is connected directly to the middle 
portion of the small intestine (jejunum), bypassing the 
rest of the stomach and the upper portion of the small 
intestine (duodenum). 
- reduces body weight 
- improves glycaemic control 
- improves PASI and DLQI 
- decreases number of dermal γδ T-
cells and IL-17 mRNA expression in 
psoriatic lesions 
- increases circulating iNKT cells 
decreases and plaque iNKT cells 
 
- Increases GLP-1 levels 
- Immediately improvement of 
psoriasis before any weight loss  
 
Figure 2.  Effects of GLP-1 receptor agonists and gastric bypass surgery in psoriatic patients with diabetes and obesity 
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Table 1 Study outcomes 
Study Study design Intervention Participants Variables Results 
T. Ahern et al, 
2013 
Prospective 
cohort study 
10 weeks of liraglutide therapy: 
self-administered by 
subcutaneous injection; 0.6mg 
daily for 2 weeks and 1.2mg daily 
for 8 weeks 
Psoriasis patients with 
diabetes and obesity  
(median age 48 years, 
median BMI 48.2 
Kg/m2)  
n = 7 
- PASI 
- DLQI 
- Circulating iNKT 
number 
- Monocyte cytokine 
production  
At week 10 
- median PASI dropped from 4.8 (2.6–11.4) to 3.0 
(1.9–7.9, P = 0.03) 
- median DLQI dropped from 6 (3.5–8.9) to 2 (1–
6.1, P = 0.03) 
- median circulating iNKT cell percentage 
increased 37.9% (18.5–234.6, P = 0.03) 
- PBMC TNFα production decreased by a median 
of 53% 
 
A.Faurschou 
et al, 2014 
 
Randomized 
placebo-
controlled 
trial 
Once-daily subcutaneous 
injections with liraglutide or 
placebo, for 8 weeks; 0.6mg for 1 
week, 1.2mg the following week 
and then 1.8mg 
Glucose-tolerant and 
obese patients (BMI > 
25 Kg/m2) with plaque 
psoriasis 
Placebo n = 9 
Liraglutide n = 11 
- PASI 
- DLQI 
- Weight 
- hsCRP 
- Adverse events 
 
At week 8 
- mean PASI decrease 2.6 ± 2.1 (mean ± SD, 
P=0.026) in the liraglutide group; non-significant 
change in PASI in the placebo group (-1.3 ± 2.4, 
P=0.141) 
- no significant differences were observed in the 
DLQI 
- the liraglutide group had a significant loss in 
bodyweight compared with the placebo group 
- no significant changes in hsCRP occurred in 
both groups 
- no major adverse events were observed 
 
M.Buysschaert 
et al, 2014 
 
Prospective 
case-series 
Patients self-administered 
subcutaneous injections with 
exenatide (5µg twice daily) or 
liraglutide (0.6mg once a day for 
1 week and then 1.2mg once a 
day). 
The variables were measured at 
baseline (T0) and 7±1 (T1) and 
18±2 (T2) weeks after treatment 
with liraglutide/exenatide. 
Patients with type 2 
diabetes and chronic 
psoriasis plaques 
(mean age 56 ± 8 
years, mean BMI 32.0 
± 10.1 Kg/m2) 
n = 7 
- PASI 
- BMI 
- HbA1c 
- dermal γδ T-cell 
percentage 
- IL-17 expression 
 
- Psoriasis severity improved with 
liraglutide/exenatide treatment (12.0±5.9 (T0), 
9.2±6.2 (T1) and 9.2±6.4 (T2)) 
- BMI decreased after  4-5 months of treatment 
(from 32.0±10.1(T0) to 30.6±9.1 (T2) Kg/m2, 
P=0.05) 
- Glycaemic control improved at T2 (HbA1c 
decreased from 7.5±1.2 (T0) to 6.5±0.8 (T2), 
P=0.014) 
- Dermal γδ T-cell percentage was higher in 
psoriatic lesions compared with unaffected skin 
and a decreased of 4.0±0.7% (P=0.05) occurred in 
the patients with improved (n=5) or unchanged 
(n=1) PASI scores during the treatment.  
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- No significance difference was seen during the 
treatment in IL-17 expression. 
 
Hogan et al, 
2011 
 
Prospective 
study 
Index patient: underwent 
treatment with exenatide for 2 
months and then with liraglutide. 
Other patients: two additional 
patients started liraglutide for 6 
weeks, after the improvement of 
psoriatic lesions in the index 
patient 
Patients with type 2 
diabetes and psoriasis 
(n=2) 
- PASI 
- circulatory and 
plaques levels of iNKT 
cell 
- GLP-1 receptor 
expression on iNKT 
cells 
- PASI improved from 13.2 to 10.8 (patient 1) 
and from 4.8 to 3.8 (patient 2) 
- circulatory iNKT cell number increased after the 
treatment and plaque iNKT cell decreased 
- iNKT cells express GLP-1R, which respond to 
GLP-1 activating a signalling pathway 
Faurschou et 
al, 2013 
Cross-
sectional 
study 
A skin biopsy was made every 
healthy volunteer and two skin 
biopsies every psoriasis patients 
(from affected and unaffected 
skin). They collected a blood 
sample from all participants and 
cultured human keratinocytes 
were stimulated or unstimulated. 
Health volunteers 
(n=6) vs Psoriasis 
patients (n=6) 
- Expression of GLP-1 
receptors in skin 
biopsies, blood samples 
and cultured human 
keratinocytes 
- GLP-1 receptors were expressed in five of six 
skin biopsies from psoriasis plaques, in one of six 
biopsies from unaffected psoriatic skin and in one 
of six biopsies from healthy skin. 
- GLP-1 receptors were expressed in the blood of 
all participants. 
- GLP-1 receptors expression were not found in 
stimulated or unstimulated cultured human 
keratinocytes. 
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Table 2. Case reports 
Study Patient Medical History Physical examination Treatment Results 
A.Faurschou et al, 
2014 
59 years 
Man 
 
 
 
- Type 2 diabetes (inadequate 
glycaemic control) 
- Hypertension 
- Hypercholesterolemia 
- Acute myocardial infarction  
- Plaque psoriasis (diagnosed 
15 years ago)  
 
- BMI 29.3 kg/m2 
- HbA1c 8.9% (74mmol/mol) 
- Psoriasis was located on the 
elbows, knees, scalp, buttocks 
and dorsal parts of the hands 
- Physician’s global assessment 
(PGA) score 3 
- Liraglutide: 0.6mg once 
daily for 1 week and then 1.2 
mg once daily the following 5 
weeks and then 1.8mg. 
- Metformin: 1g twice a day 
- Insulin?? 
After 3 months of treatment: 
- HbA1c reduced (5.9%) 
- BMI 26.81 kg/m2 
- Adverse events - nausea and 
headache, intermittent 
constipation and diarrhoea. No 
episodes of hypoglycaemia were 
reported 
- Psoriasis symptoms improved 
- PGA reduced (score 1)  
 
M.Buysschaert et 
al, 2012 
61 years 
Man  
 
 
 
 
 
- Type 2 diabetes for 14 years 
- Hypertension 
- Dyslipidaemia  
- Psoriasis (since 1980) 
 
- BMI 25.5 kg/m2 
- HbA1c 8.1% (65mmol/mol) 
- CRP 0.22 mg/dL 
- PASI score 11 
 
- Exenatide 2x5µg/day 
(initiated on September 2008) 
- Metformin and 
sulphonylureas 
- Perindopril (5mg/day) 
- Moxonidine (0.4mg/day) 
- Simvastatin (20mg/day) 
After 12 months of treatment: 
- BMI 24.07 kg/m2 
- HbA1c 7.3% (56mmol/mol) 
- CRP 0.03 md/dL 
- PASI score 3-4 (he stopped all 
topical treatments) 
 
Exenatide treatment interrupted 
in September 2009: 
- PASI score (after 6 months) >10 
- weight gain and worsening of 
glycaemic control (HbA1c 9.2%) 
 
April 2010, started exenatide 
treatment again: 
- weight loss 
- HbA1c 8.1% (65mmol/mol) 
- PASI score 3.1 
 
Reid et al, 2013 54 years 
Man  
 
 
- Extensive plaque psoriasis 
- Malignant melanoma (without 
metastatic disease) 
- No diabetes  
- BMI 42.1 kg/m2 
- PASI 14.2 
- DLQI 25 
- Acitretin 50mg daily 
- Liraglutide (0.6mg daily for 
one week and then 3mg daily) 
After one year: 
- PASI 7.6 
- DLQI 12 
- Weight decreased 10kg 
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